A Novel Oxidovanadium (IV)-Orotate Complex as an Alternative Antidiabetic Agent: Synthesis, Characterization, and Biological Assessments

Table 4

Biochemical effects of the oxidovanadium (IV)-orotate complex in vivo.

Molecule of interest	Group I	Group II	Group III	Group IV
Insulin (IU/mL)	57.64±1.76	23.78±2.50	41.44±1.23	42.67±1.77
Glucose (mg/dL)	77.55±4.93	410.23±14.52	283.51±9.21	273.77±5.11
GPT (U/L)	72.33±7.43	111.50±8.39	124.31±9.66	106.45±4.95
Creatinine (mg/dL)	0.52±0.12	1.14±0.18	0.85±0.15	0.77±0.13
Uric acid (mg/dL)	3.52±0.24	4.79±0.37	3.86±0.29	3.81±.28
LDH (U/L)	295.43±15.33	409.55±13.27	434.72±19.76	390.41±14.22
G6PD (U/L)	12.13±0.64	7.92±0.47	9.25±.41	10.13±0.41
Hb(g/dL)	12.82±.44	9.83±0.37	10.85±0.51	11.39±0.61
SOD (U/mL)	307.53±15.15	259.41±21.66	280.37 ±18.76	281.65±17.55
TC (mg/dL)	75.66±7.65	210.52±10.57	129.66±8.77	127.48±5.69
TG(mg/dL)	139.67±9.45	197.46±11.86	156.77±10.56	154.43±9.34
HDL-c (mg/dL)	42.33±3.12	21.44±1.77	32.32±2.11	34.43±3.22
LDL-c (mg/dL)	31.33±4.22	52.57±5.32	42.88±4.71	39.33±4.32